This article is more than 5 years old. Information may no longer be current.

Bausch & Lomb enters ophthalmic drug promotion, IOL material licensing agreements

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bausch & Lomb recently announced separate agreements on ophthalmic prescription drug promotion and development of IOL materials.

Under the promotion agreement, Bausch & Lomb and Pfizer will co-promote ophthalmic medications from both companies in the United States.

The 5-year pact will allow both companies to increase support for several ophthalmic medications: Pfizer's Xalatan (latanoprost ophthalmic solution) and Bausch & Lomb's Alrex (loteprednol etabonate ophthalmic suspension 0.2%), Lotemax (loteprednol etabonate ophthalmic suspension 0.5%) and Zylet (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension), according to a press release. The agreement also applies to Bausch & Lomb's besifloxacin ophthalmic suspension 0.6%, an anti-infective eye drop currently under U.S. Food and Drug Administration review.

Under the terms of the agreement, Pfizer and Bausch & Lomb sales personnel are authorized to promote Xalatan, Alrex, Lotemax, Zylet and besifloxacin, pending FDA approval, the release said. Financial terms of the promotion agreement were not released.

"This collaboration gives Pfizer Ophthalmics access to four great products, while also granting Bausch & Lomb access to Pfizer's field organization, which has deep therapeutic knowledge and expertise in ophthalmology, as well as excellent customer relationships," Jack Cox, a spokesperson for Pfizer, told Ocular Surgery News. "This partnership with Bausch & Lomb reinforces Pfizer's commitment to ophthalmology and helps us better serve the needs of eye care practitioners and patients."

Under a material licensing agreement with Santen Pharmaceutical, Bausch & Lomb has obtained the rights to Santen's hydrophobic acrylic polymers for the development of IOLs for worldwide sale.

"Bausch & Lomb is enthusiastic about the potential that these polymers hold for developing next-generation IOLs, to benefit patients and surgeons alike," John Sheets Jr., PhD, Bausch & Lomb corporate vice president and chief technology officer, said in a separate news release.

Santen retains the rights to use the materials in the Japanese market. Financial terms for the licensing agreement will not be disclosed, the release said.